Berberine (CAS 2086-83-1): AMPK Activator for Metabolic Regulation

Executive Summary: Berberine is a well-characterized isoquinoline alkaloid with a molecular weight of 336.36 and formula C₂₀H₁₈NO₄ (APExBIO). It acts as a direct activator of AMP-activated protein kinase (AMPK), leading to modulation of glucose and lipid metabolism in cellular and animal models (Li et al. 2025). In vitro studies show dose-dependent upregulation of LDL receptor (LDLR) mRNA and protein levels in human hepatoma cell lines at concentrations up to 15 μg/mL. In vivo, oral administration of 50–100 mg/kg/day reduces serum total cholesterol and LDL in hyperlipidemic hamster models. Berberine demonstrates robust anti-inflammatory and antimicrobial properties, making it a valuable tool for metabolic, cardiovascular, and inflammation research (see translational insights).

Biological Rationale

Berberine is primarily isolated from Cortex Phellodendri Chinensis and has been used traditionally for its antimicrobial and metabolic effects (APExBIO). Its molecular structure (C₂₀H₁₈NO₄) confers low solubility in water and ethanol but high solubility in DMSO (≥14.95 mg/mL). The compound’s main research applications are in metabolic disease models, including diabetes, obesity, and cardiovascular disorders, due to its ability to modulate central metabolic pathways. AMPK activation is a critical cellular energy sensor mechanism, and berberine’s direct effect on this pathway is well-documented. This rationale underlies its use for investigating glucose uptake, lipid metabolism, and inflammation (compared to prior AMPK-focused work).

Mechanism of Action of Berberine (CAS 2086-83-1)

Berberine activates AMPK, a central regulator of energy homeostasis, in multiple tissue types. AMPK activation results in increased glucose uptake and enhanced fatty acid oxidation. In hepatoma cell models (HepG2, Bel-7402), berberine induces dose-dependent upregulation of LDLR mRNA and protein, with maximal response at 15 μg/mL. This leads to increased hepatic clearance of LDL cholesterol from circulation. Berberine also modulates inflammatory pathways by interfering with NLRP3 inflammasome activation, a key mediator of sterile inflammation in acute and chronic disease models (Li et al. 2025). These mechanisms contribute to its observed effects in both metabolic and inflammatory research settings (for advanced inflammasome modulation, see related article).

Evidence & Benchmarks

• Berberine upregulates LDLR mRNA and protein in HepG2 and Bel-7402 cells in a dose-dependent manner, with maximal effect at 15 μg/mL (APExBIO, product page).
• Oral dosing in hyperlipidemic female golden hamsters at 50 or 100 mg/kg/day for 10 days significantly lowers total cholesterol and LDL levels; effect is dose- and time-dependent (APExBIO, product page).
• Berberine activates AMPK, leading to enhanced fatty acid oxidation and glucose uptake in metabolic tissue models (internal source).
• In models of acute kidney injury, modulation of the NLRP3 inflammasome by agents such as berberine has been shown to attenuate inflammation and improve survival (Li et al. 2025).
• Berberine is insoluble in water and ethanol, but soluble in DMSO (≥14.95 mg/mL); optimal dissolution requires warming to 37°C or ultrasonic agitation (APExBIO, product page).

Applications, Limits & Misconceptions

Berberine is widely used in preclinical models of diabetes, obesity, hyperlipidemia, and cardiovascular disease. Its primary application is elucidating mechanisms of metabolic regulation, particularly via AMPK activation and LDLR upregulation. Inflammation models leverage berberine’s ability to modulate the NLRP3 inflammasome, as evidenced in acute kidney injury research (Li et al. 2025). The compound is not orally bioavailable in humans at levels comparable to animal models, and its rapid metabolism limits systemic exposure. Misconceptions include overestimating its effect size in human metabolic disorders without considering pharmacokinetic constraints.

Common Pitfalls or Misconceptions

• Berberine is not highly water-soluble; improper dissolution can confound experimental results.
• Human oral bioavailability is low; animal model doses do not directly translate to clinical settings.
• It is not a direct substitute for statins or other LDL-lowering agents in clinical care.
• Long-term storage of dissolved berberine (especially above -20°C) leads to degradation and loss of activity.
• The anti-inflammatory effects are context-dependent and may not generalize to all models of sterile inflammation.

Workflow Integration & Parameters

For laboratory use, berberine (N1368) is supplied as a solid and should be stored at -20°C, sealed and protected from moisture. Dissolution in DMSO at ≥14.95 mg/mL is recommended, with warming to 37°C or ultrasonic agitation to speed solubilization. Stock solutions are best used promptly; avoid storage above -20°C. In cell culture, concentrations up to 15 μg/mL are validated for LDLR upregulation in hepatoma lines. Animal studies commonly use 50–100 mg/kg/day oral dosing in hyperlipidemic models. For advanced metabolic and inflammasome research, refer to this recent review—which this article extends by providing new evidence benchmarks and machine-readable parameters.

Conclusion & Outlook

Berberine (CAS 2086-83-1) from APExBIO is a validated molecular tool for studying AMPK-dependent metabolic regulation and LDLR upregulation in vitro and in vivo. Its robust, dose-dependent effects on lipid and glucose metabolism, alongside anti-inflammatory activity via NLRP3 modulation, make it indispensable in metabolic disease research. While translational hurdles exist—primarily due to solubility and pharmacokinetic constraints—berberine remains a standard for preclinical workflow optimization. For further translational insights and comparative molecular mechanisms, see Berberine: Translational Insights from AMPK to Kidney Models, which this article updates with new experimental benchmarks.